Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 1.00 |
| ▸ | TEK | Q02763 | 11/20 | 1.00 |
| ▸ | KIT | P10721 | 10/20 | 1.00 |
| ▸ | FLT1 | P17948 | 6/20 | 1.00 |
| ▸ | FLT4 | P35916 | 4/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 5/20 | 0.73 |
| ▸ | CSNK1G2 | P78368 | 5/20 | 0.73 |
| ▸ | HIPK4 | Q8NE63 | 5/20 | 0.73 |
| ▸ | SLK | Q9H2G2 | 5/20 | 0.73 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.73 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.73 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.73 |
| ▸ | LCK | P06239 | 4/20 | 0.73 |
| ▸ | CSF1R | P07333 | 4/20 | 0.73 |
| ▸ | LYN | P07948 | 4/20 | 0.73 |
| ▸ | RET | P07949 | 4/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.73 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.73 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.73 |
| ▸ | FLT3 | P36888 | 4/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466518 | 0.88 | KDR (1.00) | KDRTEKKITFLT1FLT4 | |
| SCHEMBL4468494 | 0.87 | KDR (1.00) | KDRTEKKITFLT1FLT4 | |
| SCHEMBL4462026 | 0.85 | KDR (1.00) | KDRTEKKITFLT1FLT4 | |
| SCHEMBL4468181 | 0.84 | KDR (1.00) | KDRTEKKITFLT1FLT4 | |
| SCHEMBL4489725 | 0.83 | KDR (1.00) | KDRTEKKITFLT1FLT4 | |
| SCHEMBL232042 | 0.82 | KDR (1.00) | KDRTEKKITFLT1FLT4 | |
| SCHEMBL4467321 | 0.82 | KDR (1.00) | KDRTEKKITFLT1FLT4 | |
| SCHEMBL4471326 | 0.80 | KDR (0.82) | KDRTEKKITFLT1FLT4 | |
| SCHEMBL3121363 | 0.80 | KDR (1.00) | KDRTEKKITFLT1FLT4 | |
| SCHEMBL12808098 | 0.79 | AURKB (1.00) | KDRTEKKITFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487841-B1 | THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS | ABBVIE INC (US) | 2014-01-15 | — | — | EP | claimed |
| US-7560552-B2 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES (US) | 2009-07-14 | — | — | US | claimed |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-09-25 | — | — | US | claimed |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FOUNTAIN THERAPEUTICS INC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-1487841-B1 | THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS | ABBVIE INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-7560552-B2 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES (US) | 2009-07-14 | — | — | US | disclosed |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | MICHAELIDES MICHAEL R | 2006-12-07 | — | — | US | disclosed |
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | disclosed |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KDR 425/4885TEK 328/4885KIT 394/4885 |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | ABL1, LCK, ERBB2 | KDR 391/4885TEK 324/4885KIT 361/4885 |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KDR 425/4885TEK 328/4885KIT 394/4885 |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FGFR1, FRS2, FGFR2 | KDR 5/4885TEK 6/4885KIT 474/4885 |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KDR 462/4885TEK 340/4885KIT 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.